First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects

被引：0
|
作者：
Jingyi Wang [1 ,2 ]
Lin Wu [1 ]
机构：
[1] The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
[2] Xiangya Lung Cancer Center, Xiangya Hospital, Central South University
来源：
Cancer Biology & Medicine | 2024年 / 02期
关键词：
D O I：
暂无
中图分类号：
R734.2 [肺肿瘤];
学科分类号：
100214 ;
摘要：
Global Cancer Statistics 2022 reported the prevalence and high mortality rate of lung cancer. Notably, non-small cell lung cancer(NSCLC) accounts for the majority of the histologic types1. Precision therapy for lung cancer has progressed rapidly and immune checkpoint inhibitors(ICIs) have become a leading research topic. Indeed, ICI therapy has been shown to improve the prognosis of lung cancer patients.
引用
收藏
页码：117 / 124
页数：8
相关论文
共 50 条
  • [1] First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects
    Wang, Jingyi
    Wu, Lin
    CANCER BIOLOGY & MEDICINE, 2024, 21 (02) : 117 - 124
  • [2] Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
    Ryu, Rachel
    Ward, Kristina E.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
    Spagnuolo, Alessia
    Gridelli, Cesare
    CANCERS, 2023, 15 (08)
  • [4] First-line immunotherapy in advanced non-small-cell lung cancer
    Noronha, Vanita
    Mehta, Prashant
    Malik, Prabhat Singh
    Patel, Amol
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) : 461 - 462
  • [5] First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
    Huang, Zhangfeng
    Su, Wenhao
    Lu, Tong
    Wang, Yuanyong
    Dong, Yanting
    Qin, Yi
    Liu, Dahai
    Sun, Lili
    Jiao, Wenjie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [6] First-line combination immunotherapy for metastatic non-small cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
  • [7] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [8] Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review
    Guo, Haiyang
    Zhang, Jun
    Qin, Chao
    Yan, Hang
    Luo, Xinyue
    Zhou, Haining
    MEDICINE, 2024, 103 (03) : E36861
  • [9] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    Martinez, Pablo
    Peters, Solange
    Stammers, Timothy
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698
  • [10] First-line immunotherapy in non-small cell lung cancer diagnosed with brain metastases
    Nigen, B.
    Bodergat, T.
    Vaugier, L.
    Pons-Tostivint, E.
    REVUE DES MALADIES RESPIRATOIRES, 2024, 41 (08) : 571 - 582
12345